Rapamycin is a triene macrolide antibiotic,which demonstrates anti-fungal,anti-inflammatory,anti-tumor and
immunosuppressive properties.
Rapamycin has been shown to block T-cell activation and proliferation,as well as,the activation of p70 S6 kinase and
exhibits strong binding to FK506 binding proteins.
Rapamycin also inhibits the activity of the protein,mTOR(mammalian target of rapamycin) which functions in a
signaling pathway to promote tumor growth.
Rapamycin binds to a receptor protein (FKBP12) and the rapamycin/FKB12 complex then binds to mTOR and prevents
interaction of mTOR with target proteins in this signaling pathway.
Rapamycin (RAPA) is a novel macrolide immunosuppressant is now often used as a transplanted organ to maintain
immunity drugs (especially kidney transplants), to mitigate the immune organ rejection after transplant surgery, but
scientists it recently found another purpose: for the treatment of Alzheimer's disease (senile dementia).
Target of rapamycin (mTOR) as an intracellular kinases pathway abnormalities can induce a variety of diseases. As
rapamycin mTOR inhibitor targeting, to treat with this pathway is closely related to tumors, including renal cell
carcinoma, lymphoma, lung cancer, liver cancer, breast cancer, neuroendocrine carcinoma and gastric cancer
Pemasok yang Diaudit 
Pemasok yang Diaudit 
